Revision as of 07:55, 31 March 2009 editMeodipt (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers35,763 editsNo edit summary← Previous edit | Revision as of 08:17, 31 March 2009 edit undoMeodipt (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers35,763 editsNo edit summaryNext edit → | ||
Line 26: | Line 26: | ||
}} | }} | ||
'''LY-344,545''' is a research drug developed by the pharmaceutical company ], which acts as an antagonist for the metabotropic glutamate receptor subtype ]. It is an ] of another metabotropic glutamate receptor antagonist, the ]-selective ].<ref>Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. ''British Journal of Pharmacology''. 2000 Sep;131(2):239-44. PMID 10991916</ref> | '''LY-344,545''' is a research drug developed by the pharmaceutical company ], which acts as an ] for the ] subtype ]. It is an ] of another metabotropic glutamate receptor antagonist, the ]-selective ].<ref>Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. ''British Journal of Pharmacology''. 2000 Sep;131(2):239-44. PMID 10991916</ref> | ||
Revision as of 08:17, 31 March 2009
Pharmaceutical compoundChemical and physical data | |
---|---|
Formula | C20H19NO5 |
Molar mass | 353.37 g/mol g·mol |
LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3-selective LY-341,495.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |
References
- Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology. 2000 Sep;131(2):239-44. PMID 10991916